Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02517398 · ClinicalTrials.gov registry record · Phase 1
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
A Phase 1 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 600
- Enrollment target
NCT02517398 is a Phase 1 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 600 participants.
The verdict
NCT02517398, a Phase 1 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 600 participants
- Enrollment target
Study Summary
The main purpose of this Phase I study was to test MSB0011359C (M7824) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks. Phase I means the study drug has not previously been given to humans or has only been given to a limited number of people, although it has been extensively studied in animals. Based on this information, it is hoped to find out which dose could be best for the treatment of patients. There are two parts of this research study: a dose-escalation part and an expansion part. Dose escalation means that the first people taking part in the study will receive low doses of the study drug, and as more people take part, the additional participants will receive a higher dose. This is done to find the safest dose for the study drug. Expansion means that after the dose-escalation part of the study has looked at the safety and effectiveness of different doses, many more people will be invited to take part in the study and will receive the study drug at the safest dose. Additional purposes of the study are to find out whether the study drug has anti-cancer effects and how the study drug is processed by the body.
Interventions
- DRUG MSB0011359C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2015-08-31 |
| Est. Completion | 2022-05-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02517398
The ClinicalTrials.gov registry entry for NCT02517398 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MSB0011359C is the first listed.
NCT02517398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02517398 about?
NCT02517398 is a clinical study titled "MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors". The main purpose of this Phase I study was to test MSB0011359C (M7824) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks. Phase I means the study drug has not previously been given to humans or has only been given to a limited number of people, although i...
What is the current status of trial NCT02517398?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 600 participants. The study started on 2015-08-31. Estimated completion is 2022-05-23.
What interventions are being tested in trial NCT02517398?
The interventions under investigation include: MSB0011359C (DRUG).
Who is sponsoring clinical trial NCT02517398?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.